Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. (formerly iBioPharma, Inc.) on August 14, 2009, covering events occurring on August 10, 2009. The company is incorporated in Delaware and is headquartered in Newark, Delaware.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a corporate governance change and does not contain financial statements or performance data.
Material Changes
- Corporate Name Change: Effective August 10, 2009, the company changed its name from iBioPharma, Inc. to iBio, Inc.
- Method of Change: The change was effected through a short-form merger pursuant to Section 253 of the Delaware General Corporation Law, merging a wholly-owned subsidiary into the parent company.
- Shareholder Impact: Stockholder approval was not required, and the outstanding shares of common stock were not affected by the name change.
- Document Amendments: The Board of Directors amended the Certificate of Incorporation, Bylaws, board committee charters, and the code of business ethics to reflect the new name.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is strictly limited to the procedural details of the name change.
Key Facts for Investor Verification
- Verify the new legal name "iBio, Inc." in subsequent filings and trading symbols.
- Confirm that the short-form merger did not alter the capital structure or shareholder rights.
- Review the attached Exhibit 3.1 (Certificate of Ownership and Merger) and Exhibit 3.2 (First Amended and Restated Bylaws) for specific legal language regarding the transition.